The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
These medicines are essential in preventing RhD immunisation during pregnancy
Commercial production is expected to begin soon
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries
Subscribe To Our Newsletter & Stay Updated
